AI Summary & Key Takeaways
AI InsightAfter administration offraxiparine single dose and once a daily for seven days, the increased platelet aggregation was decreased in atherosclerotic patients.
📌 3 Key Takeaways
Abstract
In our study, the effect of fraxiparine -a low molecular weight heparin- on platelet aggregation in atherosclerotic patients was investigated. Fraxiparine was administered to the experiment group single dose and for a week subcutaneously. Platelet aggregation was examined in both groups. Platelet aggregation increased significantly in atherosclerotic patients compared to the control group. After administration offraxiparine single dose and once a daily for seven days, the increased platelet aggregation was decreased in atherosclerotic patients.
Özet
Çalışmamızda, bir düşük moleküler ağırlıklı heparin (LMWH) olan fraxiparine "m aterosklerotik hastalarda trombosit agregasyonuüzerine etkisi incelendi. Deney grubunu oluşturan hastalara fraxiparine (150 I. Ü/kg), tek doz ve yedi gün tekrarlayan dozlar şeklinde subkutan olarak uygulandı. Kontrol ve deney gruplarında trombosit agregasyonları incelendi. Aterosklerozhı hasta grubunun trombosit agregasyonunda, kontrol grubuna göre anlamlı bir artış vardı. Hasta grubuna fraxiparine'in tek doz ve yedi gün uygulanması sonucunda, aterosklerotik hastalarda gözlenen artmış trombosit agregasyonunda azalma gözlendi.